| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | Nesina, Vipidia SYR-322 | |
| 3 | Generic Name | alogliptin | |
| 4 | Indication | Type 2 Diabetes | |
| 5 | Economics | PPDI | |
| 6 | Safety | Have not seen skin toxicity in animals. | |
| 7 | Timeline | NDA submitted 1/4/2008. FDA now asking for CV studies, and Takeda is delaying EU filing until 2012. | |
| 8 | Competition | Januvia (MRK). $42m. $87m. $144m. $185m. Q1-Q4 of launch. | |
| 9 | BMY, NVS (Galvus). | ||
| 10 | Clinical Trials | ||
| 11 | Phase 3 trials - 6 conducted | ||
| 12 | 3 deaths in studies--2 unrelated and one possibly related. |